{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:35:15Z","timestamp":1770327315695,"version":"3.49.0"},"publisher-location":"Cham","reference-count":77,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319689463","type":"print"},{"value":"9783319689487","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/82_2017_53","type":"book-chapter","created":{"date-parts":[[2017,9,16]],"date-time":"2017-09-16T00:44:25Z","timestamp":1505522665000},"page":"229-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Accelerating Vaccine Development During the 2013\u20132016 West African Ebola Virus Disease Outbreak"],"prefix":"10.1007","author":[{"given":"Elizabeth S.","family":"Higgs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri A.","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A. G.","family":"Coller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub K.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bollinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Sorenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barthalomew","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha C.","family":"Nason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa E.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,17]]},"reference":[{"issue":"9","key":"53_CR1","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1128\/jvi.02696-06","volume":"81","author":"P Abbink","year":"2007","unstructured":"Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O\u2019Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81(9):4654\u20134663. doi: 10.1128\/jvi.02696-06","journal-title":"J Virol"},{"issue":"17","key":"53_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","volume":"374","author":"ST Agnandji","year":"2016","unstructured":"Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaitre B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmuller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA (2016) Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374(17):1647\u20131660. doi: 10.1056\/NEJMoa1502924","journal-title":"N Engl J Med"},{"issue":"15","key":"53_CR3","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","volume":"371","author":"S Baize","year":"2014","unstructured":"Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keita S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traore A, Kolie M, Malano ER, Heleze E, Bocquin A, Mely S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Gunther S (2014) Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371(15):1418\u20131425. doi: 10.1056\/NEJMoa1404505","journal-title":"N Engl J Med"},{"key":"53_CR4","unstructured":"Bolay F (2016) A randomized controlled trial of the safety and immunogenicity of two Ebola vaccines. In: Abstracts of the 23rd Conference on Retroviruses and Opportunistic Infections, John B Hynes Veterans Memorial Convention Center, Boston, 22\u201325 Feb 2016. Abstract 76LB. CROI Foundation\/International Antiviral Society-USA, San Francisco, CA. http:\/\/www.croiconference.org\/sessions\/randomized-controlled-trial-safety-and-immunogenicity-two-ebola-vaccines . Accessed 7 Apr 2017"},{"key":"53_CR5","unstructured":"Bray M, Chertow DS (2016) Epidemiology and pathogenesis of Ebola virus disease. UpToDate, Wolters Kluwer. https:\/\/www.uptodate.com\/contents\/epidemiology-and-pathogenesis-of-ebola-virus-disease?source=search_result&search=bray%20ebola&selectedTitle=3~23 . Accessed 10 Apr 2017"},{"issue":"10066","key":"53_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s0140-6736(17)30131-9","volume":"389","author":"B Brende","year":"2017","unstructured":"Brende B, Farrar J, Gashumba D, Moedas C, Mundel T, Shiozaki Y, Vardhan H, Wanka J, Rottingen JA (2017) CEPI-a new global R&D organisation for epidemic preparedness and response. Lancet 389(10066):233\u2013235. doi: 10.1016\/s0140-6736(17)30131-9","journal-title":"Lancet"},{"key":"53_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2016-103474","author":"P Calain","year":"2016","unstructured":"Calain P (2016) The Ebola clinical trials: a precedent for research ethics in disasters. J Med Ethics. doi: 10.1136\/medethics-2016-103474","journal-title":"J Med Ethics"},{"issue":"4","key":"53_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1586\/erv.13.15","volume":"12","author":"S Capone","year":"2013","unstructured":"Capone S, D\u2019Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A (2013) Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccin 12(4):379\u2013393. doi: 10.1586\/erv.13.15","journal-title":"Expert Rev Vaccin"},{"issue":"3","key":"53_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/s1473-3099(15)00486-7","volume":"16","author":"O Santis De","year":"2016","unstructured":"De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F, Genton B (2016) Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study. Lancet Infect Dis 16(3):311\u2013320. doi: 10.1016\/s1473-3099(15)00486-7","journal-title":"Lancet Infect Dis"},{"key":"53_CR10","unstructured":"d\u2019Harcourt E (2016) The Ebola lessons reader: what\u2019s being said, what\u2019s missing and why it matters. International Rescue Committee. https:\/\/www.rescue.org\/sites\/default\/files\/document\/563\/theebolalessonsreaderlowres.pdf . Accessed 3 May 2017"},{"key":"53_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.conctc.2016.06.008","volume":"4","author":"J Doe-Anderson","year":"2016","unstructured":"Doe-Anderson J, Baseler B, Driscoll P, Johnson M, Lysander J, McNay L, Njoh WS, Smolskis M, Wehrlen L, Zuckerman J (2016) Beating the odds: successful establishment of a phase II\/III clinical research trial in resource-poor Liberia during the largest-ever Ebola outbreak. Contemp Clin Trials Commun 4:68\u201373. doi: 10.1016\/j.conctc.2016.06.008","journal-title":"Contemp Clin Trials Commun"},{"issue":"3","key":"53_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","volume":"13","author":"IV Dolzhikova","year":"2017","unstructured":"Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Tokarskaya EA, Simakova YV, Egorova DA, Scherbinin DN, Tutykhina IL, Lysenko AA, Kostarnoy AV, Gancheva PG, Ozharovskaya TA, Belugin BV, Kolobukhina LV, Pantyukhov VB, Syromyatnikova SI, Shatokhina IV, Sizikova TV, Rumyantseva IG, Andrus AF, Boyarskaya NV, Voytyuk AN, Babira VF, Volchikhina SV, Kutaev DA, Bel\u2019skih AN, Zhdanov KV, Zakharenko SM, Borisevich SV, Logunov DY, Naroditsky BS, Gintsburg AL (2017) Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I\/II trial in healthy adults in Russia. Hum Vaccin Immunother 13(3):613\u2013620. doi: 10.1080\/21645515.2016.1238535","journal-title":"Hum Vaccin Immunother"},{"key":"53_CR13","doi-asserted-by":"publisher","unstructured":"Dudas G, Carvalho LM, Bedford T, Tatem AJ, Baele G, Faria NR, Park DJ, Ladner JT, Arias A, Asogun D, Bielejec F, Caddy SL, Cotten M, D\u2019Ambrozio J, Dellicour S, Caro AD, Diclaro JW, Duraffour S, Elmore MJ, Fakoli LS, Faye O, Gilbert ML, Gevao SM, Gire S, Gladden-Young A, Gnirke A, Goba A, Grant DS, Haagmans BL, Hiscox JA, Jah U, Kugelman JR, Liu D, Lu J, Malboeuf CM, Mate S, Matthews DA, Matranga CB, Meredith LW, Qu J, Quick J, Pas SD, Phan MVT, Pollakis G, Reusken CB, Sanchez-Lockhart M, Schaffner SF, Schieffelin JS, Sealfon RS, Simon-Loriere E, Smits SL, Stoecker K, Thorne L, Tobin EA, Vandi MA, Watson SJ, West K, Whitmer S, Wiley MR, Winnicki SM, Wohl S, W\u00f6lfel R, Yozwiak NL, Andersen KG, Blyden SO, Bolay F, Carroll MW, Dahn B, Diallo B, Formenty P, Fraser C, Gao GF, Garry RF, Goodfellow I, G\u00fcnther S, Happi CT, Holmes EC, Kargbo B, Ke\u00efta S, Kellam P, Koopmans MPG, Kuhn JH, Loman NJ, Magassouba NF, Naidoo D, Nichol ST, Nyenswah T, Palacios G, Pybus OG, Sabeti PC, Sall A, Str\u00f6her U, Wurie I, Suchard MA, Lemey P, Rambaut A (2017) Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature. doi: 10.1038\/nature22040 . http:\/\/www.nature.com\/nature\/journal\/vaop\/ncurrent\/abs\/nature22040.html#supplementary-information . Accessed 13 Apr 2017","DOI":"10.1038\/nature22040"},{"issue":"17","key":"53_CR14","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K Ewer","year":"2016","unstructured":"Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krahling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbe G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV (2016) A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med 374(17):1635\u20131646. doi: 10.1056\/NEJMoa1411627","journal-title":"N Engl J Med"},{"issue":"1","key":"53_CR15","doi-asserted-by":"publisher","first-page":"e1002227","DOI":"10.1371\/journal.pmed.1002227","volume":"14","author":"MP Fallah","year":"2017","unstructured":"Fallah MP, Skrip LA, Raftery P, Kullie M, Borbor W, Laney AS, Blackley DJ, Christie A, Dokubo EK, Lo TQ, Coulter S, Baller A, Vonhm BT, Bemah P, Lomax S, Yeiah A, Wapoe-Sackie Y, Mann J, Clement P, Davies-Wayne G, Hamblion E, Wolfe C, Williams D, Gasasira A, Kateh F, Nyenswah TG, Galvani AP (2017) Bolstering community cooperation in Ebola resurgence protocols: combining field blood draw and point-of-care diagnosis. PLoS Med 14(1):e1002227. doi: 10.1371\/journal.pmed.1002227","journal-title":"PLoS Med"},{"issue":"9919","key":"53_CR16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/s0140-6736(14)60189-6","volume":"383","author":"TR Frieden","year":"2014","unstructured":"Frieden TR, Tappero JW, Dowell SF, Hien NT, Guillaume FD, Aceng JR (2014) Safer countries through global health security. Lancet 383(9919):764\u2013766. doi: 10.1016\/s0140-6736(14)60189-6","journal-title":"Lancet"},{"key":"53_CR17","unstructured":"Grady D (2014) Ebola vaccine, ready for test, sat on the shelf. N Y Times, 23 Oct 2014. https:\/\/www.nytimes.com\/2014\/10\/24\/health\/without-lucrative-market-potential-ebola-vaccine-was-shelved-for-years.html?_r=1 . Accessed 27 Apr, 2017"},{"issue":"Suppl 3","key":"53_CR22","doi-asserted-by":"publisher","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","volume":"204","author":"TW Geisbert","year":"2011","unstructured":"Geisbert TW, Feldmann H (2011) Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 204(Suppl 3):S1075\u2013S1081. doi: 10.1093\/infdis\/jir349","journal-title":"J Infect Dis"},{"issue":"52","key":"53_CR18","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","volume":"26","author":"TW Geisbert","year":"2008","unstructured":"Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Stroher U, Fritz EA, Hensley LE, Jones SM, Feldmann H (2008a) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26(52):6894\u20136900. doi: 10.1016\/j.vaccine.2008.09.082","journal-title":"Vaccine"},{"issue":"11","key":"53_CR19","doi-asserted-by":"publisher","first-page":"e1000225","DOI":"10.1371\/journal.ppat.1000225","volume":"4","author":"TW Geisbert","year":"2008","unstructured":"Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, Hensley LE, Feldmann H, Jahrling PB (2008b) Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 4(11):e1000225. doi: 10.1371\/journal.ppat.1000225","journal-title":"PLoS Pathog"},{"issue":"14","key":"53_CR20","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1128\/jvi.00561-09","volume":"83","author":"TW Geisbert","year":"2009","unstructured":"Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H (2009) Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 83(14):7296\u20137304. doi: 10.1128\/jvi.00561-09","journal-title":"J Virol"},{"issue":"9","key":"53_CR21","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1128\/jvi.02407-10","volume":"85","author":"TW Geisbert","year":"2011","unstructured":"Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ (2011) Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against Ebolavirus challenge. J Virol 85(9):4222\u20134233. doi: 10.1128\/jvi.02407-10","journal-title":"J Virol"},{"key":"53_CR24","unstructured":"Hankins C (2016) Good participatory practice guidelines for trials of emerging (and re-emerging) pathogens that are likely to cause severe outbreaks in the near future and for which few or no medical countermeasures exist (GPP-EP). Outcome document of the consultative process. World Health Organization. http:\/\/www.who.int\/csr\/research-and-development\/documents\/GPP-EP-Dec-2016.pdf?ua=1 . Accessed 26 Apr 2017"},{"issue":"9996","key":"53_CR25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/s0140-6736(15)61117-5","volume":"386","author":"AM Henao-Restrepo","year":"2015","unstructured":"Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Konde MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, Keita S, Kieny MP, Rottingen JA (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386(9996):857\u2013866. doi: 10.1016\/s0140-6736(15)61117-5","journal-title":"Lancet"},{"issue":"10068","key":"53_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Konde MK, Keita S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Rottingen JA, Kieny MP (2017) Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389(10068):505\u2013518. doi: 10.1016\/s0140-6736(16)32621-6","journal-title":"Lancet"},{"issue":"9","key":"53_CR27","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1128\/jvi.03361-12","volume":"87","author":"AS Herbert","year":"2013","unstructured":"Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM (2013) Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 87(9):4952\u20134964. doi: 10.1128\/jvi.03361-12","journal-title":"J Virol"},{"issue":"10","key":"53_CR28","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/s1473-3099(15)00154-1","volume":"15","author":"A Huttner","year":"2015","unstructured":"Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krahling V, Kwilas S, Lemaitre B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA (2015) The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial. Lancet Infect Dis 15(10):1156\u20131166. doi: 10.1016\/s1473-3099(15)00154-1","journal-title":"Lancet Infect Dis"},{"key":"53_CR29","unstructured":"Institute of Medicine, Committee to Review Adverse Effects of Vaccines (2011) Adverse effects of vaccines: evidence and causality. National Academies Press, Washington, DC"},{"key":"53_CR30","unstructured":"Institute of Medicine, Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines (1991) Adverse effects of pertussis and rubella vaccines: a report of the committee to review the adverse consequences of pertussis and rubella vaccines. National Academy Press, Washington, DC"},{"issue":"suppl 3","key":"53_CR31","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","volume":"214","author":"RF Johnson","year":"2016","unstructured":"Johnson RF, Kurup D, Hagen KR, Fisher C, Keshwara R, Papaneri A, Perry DL, Cooper K, Jahrling PB, Wang JT, Ter Meulen J, Wirblich C, Schnell MJ (2016) An inactivated rabies virus-based Ebola vaccine, FILORAB1, adjuvanted With glucopyranosyl lipid A in stable emulsion confers complete protection in nonhuman primate challenge models. J Infect Dis 214(suppl 3):S342\u2013S354. doi: 10.1093\/infdis\/jiw231","journal-title":"J Infect Dis"},{"issue":"7","key":"53_CR32","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11(7):786\u2013790. doi: 10.1038\/nm1258","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"53_CR33","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.1086\/520591","volume":"196","author":"SM Jones","year":"2007","unstructured":"Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk HD, Feldmann H (2007) Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 196(Suppl 2):S404\u2013S412. doi: 10.1086\/520591","journal-title":"J Infect Dis"},{"key":"53_CR23","doi-asserted-by":"crossref","unstructured":"Kennedy S, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, S G, Hensley L, Higgs E, Janosko K, Johnson M, Kateh F, Logue J, Marchand J, Monath T, Nason M, Nyenswah T, Roman F, Stavale E, Wolfson J, Neaton J, Lane H (2017) Phase 2 placebo-controlled trial of 2 vaccines to prevent Ebola in Liberia. N Engl J Med (in press)","DOI":"10.1056\/NEJMoa1614067"},{"key":"53_CR34","doi-asserted-by":"crossref","unstructured":"Keusch G, McAdam K, Cuff P, Mancher M, Busta ER (2017) Integrating clinical research into epidemic response: the Ebola experience. National Academies Press. https:\/\/www.nap.edu\/catalog\/24739\/integrating-clinical-research-into-epidemic-response-the-ebola-experience . Accessed 26 Apr 2017","DOI":"10.17226\/24739"},{"issue":"9977","key":"53_CR35","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/s0140-6736(14)62385-0","volume":"385","author":"H Kibuuka","year":"2015","unstructured":"Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, Joshi G, Stanley D, Kunchai M, Eller LA, Bailer RT, Koup RA, Nabel GJ, Mascola JR, Sullivan NJ, Graham BS, Roederer M, Michael NL, Robb ML, Ledgerwood JE (2015) Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 385(9977):1545\u20131554. doi: 10.1016\/s0140-6736(14)62385-0","journal-title":"Lancet"},{"issue":"10027","key":"53_CR36","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/s0140-6736(16)00686-3","volume":"387","author":"MP Kieny","year":"2016","unstructured":"Kieny MP, Longini IM, Henao-Restrepo AM, Watson CH, Egger M, Edmunds WJ (2016) Changes in the primary outcome in Ebola vaccine trial\u2013Authors\u2019 reply. Lancet 387(10027):1509\u20131510. doi: 10.1016\/s0140-6736(16)00686-3","journal-title":"Lancet"},{"issue":"2","key":"53_CR37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.virol.2005.10.042","volume":"346","author":"GP Kobinger","year":"2006","unstructured":"Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM (2006) Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346(2):394\u2013401. doi: 10.1016\/j.virol.2005.10.042","journal-title":"Virology"},{"issue":"9996","key":"53_CR38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/s0140-6736(15)00002-1","volume":"386","author":"PR Krause","year":"2015","unstructured":"Krause PR (2015) Interim results from a phase 3 Ebola vaccine study in Guinea. Lancet 386(9996):831\u2013833. doi: 10.1016\/s0140-6736(15)00002-1","journal-title":"Lancet"},{"issue":"9","key":"53_CR39","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1073\/pnas.1614595114","volume":"114","author":"MS Lau","year":"2017","unstructured":"Lau MS, Dalziel BD, Funk S, McClelland A, Tiffany A, Riley S, Metcalf CJ, Grenfell BT (2017) Spatial and temporal dynamics of superspreading events in the 2014\u20132015 West Africa Ebola epidemic. Proc Natl Acad Sci U S A 114(9):2337\u20132342. doi: 10.1073\/pnas.1614595114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"53_CR40","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS (2017) Chimpanzee adenovirus vector Ebola vaccine. N Engl J Med 376(10):928\u2013938. doi: 10.1056\/NEJMoa1410863","journal-title":"N Engl J Med"},{"issue":"3","key":"53_CR41","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1016\/s2214-109x(16)30367-9","volume":"5","author":"JX Li","year":"2017","unstructured":"Li JX, Hou LH, Meng FY, Wu SP, Hu YM, Liang Q, Chu K, Zhang Z, Xu JJ, Tang R, Wang WJ, Liu P, Hu JL, Luo L, Jiang R, Zhu FC, Chen W (2017) Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health 5(3):e324\u2013e334. doi: 10.1016\/s2214-109x(16)30367-9","journal-title":"Lancet Glob Health"},{"issue":"11","key":"53_CR42","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1128\/cvi.00162-06","volume":"13","author":"JE Martin","year":"2006","unstructured":"Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS (2006) A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13(11):1267\u20131277. doi: 10.1128\/cvi.00162-06","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"53_CR43","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1073\/pnas.1209591110","volume":"110","author":"A Marzi","year":"2013","unstructured":"Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, Feldmann H, Messaoudi I (2013) Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 110(5):1893\u20131898. doi: 10.1073\/pnas.1209591110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9948","key":"53_CR44","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S0140-6736(14)61411-2","volume":"384","author":"J Maurice","year":"2014","unstructured":"Maurice J (2014) WHO meeting chooses untried interventions to defeat Ebola. Lancet 384(9948):e45\u2013e46. doi: 10.1016\/S0140-6736(14)61411-2","journal-title":"Lancet"},{"key":"53_CR01","doi-asserted-by":"crossref","unstructured":"Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, Mansfield KG, Feldmann H, Hensley LE, Geisbert TW (2012) Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS. doi: https:\/\/doi.org\/10.1371\/journal.pntd.0001567","DOI":"10.1371\/journal.pntd.0001567"},{"issue":"46","key":"53_CR45","first-page":"1082","volume":"63","author":"T Nyenswah","year":"2014","unstructured":"Nyenswah T, Fahnbulleh M, Massaquoi M, Nagbe T, Bawo L, Falla JD, Kohar H, Gasasira A, Nabeth P, Yett S, Gergonne B, Casey S, Espinosa B, McCoy A, Feldman H, Hensley L, Baily M, Fields B, Lo T, Lindblade K, Mott J, Boulanger L, Christie A, Wang S, Montgomery J, Mahoney F (2014) Ebola epidemic\u2014Liberia, March\u2013October 2014. MMWR Morb Mortal Wkly Rep 63(46):1082\u20131086","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"53_CR46","doi-asserted-by":"publisher","unstructured":"Plotkin SA (2017) Vaccines for epidemic infections and the role of CEPI. Hum Vaccin Immunother:1\u20138. doi: 10.1080\/21645515.2017.1306615","DOI":"10.1080\/21645515.2017.1306615"},{"issue":"5","key":"53_CR47","doi-asserted-by":"publisher","first-page":"e5547","DOI":"10.1371\/journal.pone.0005547","volume":"4","author":"X Qiu","year":"2009","unstructured":"Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Stroher U, Feldmann H, Jones SM (2009) Mucosal immunization of cynomolgus macaques with the VSVDeltaG\/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS ONE 4(5):e5547. doi: 10.1371\/journal.pone.0005547","journal-title":"PLoS ONE"},{"issue":"4","key":"53_CR48","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1414216","volume":"376","author":"JA Regules","year":"2017","unstructured":"Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Munoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutierrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ (2017) A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 376(4):330\u2013341. doi: 10.1056\/NEJMoa1414216","journal-title":"N Engl J Med"},{"issue":"7","key":"53_CR49","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMp1613577","volume":"376","author":"JA Rottingen","year":"2017","unstructured":"Rottingen JA, Gouglas D, Feinberg M, Plotkin S, Raghavan KV, Witty A, Draghia-Akli R, Stoffels P, Piot P (2017) New vaccines against epidemic infectious diseases. N Engl J Med 376(7):610\u2013613. doi: 10.1056\/NEJMp1613577","journal-title":"N Engl J Med"},{"issue":"10","key":"53_CR50","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nm.3702","volume":"20","author":"DA Stanley","year":"2014","unstructured":"Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, Foulds KE, Cheng C, Wang L, Donaldson MM, Colloca S, Folgori A, Roederer M, Nabel GJ, Mascola J, Nicosia A, Cortese R, Koup RA, Sullivan NJ (2014) Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20(10):1126\u20131129. doi: 10.1038\/nm.3702","journal-title":"Nat Med"},{"issue":"6812","key":"53_CR51","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/35046108","volume":"408","author":"NJ Sullivan","year":"2000","unstructured":"Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408(6812):605\u2013609. doi: 10.1038\/35046108","journal-title":"Nature"},{"issue":"6949","key":"53_CR52","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nature01876","volume":"424","author":"NJ Sullivan","year":"2003","unstructured":"Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424(6949):681\u2013684. doi: 10.1038\/nature01876","journal-title":"Nature"},{"issue":"1","key":"53_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1473-3099(15)00362-x","volume":"16","author":"MD Tapia","year":"2016","unstructured":"Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny MP, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AV, Ballou WR, Sullivan N, Graham B, Levine MM (2016) Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 16(1):31\u201342. doi: 10.1016\/s1473-3099(15)00362-x","journal-title":"Lancet Infect Dis"},{"key":"53_CR54","unstructured":"United Nations Security Council (2014) Resolution 2176 (2014) adopted by the Security Council at its 7263rd meeting, on 15 September 2014. United Nations Security Council. http:\/\/undocs.org\/S\/RES\/2176(2014 ). Accessed 28 Mar 2017"},{"key":"53_CR55","unstructured":"U.S. Department of Health and Human Services (2016) Ebola response improvement plan based on lessons learned from the 2014\u20132016 Ebola epidemic. US Department of Health and Human Services. https:\/\/www.phe.gov\/Preparedness\/responders\/ebola\/Documents\/EbolaIP.pdf . Accessed 3 May 2017, Washington, DC"},{"key":"53_CR56","unstructured":"U.S. Department of Health and Human Services (2017) Ebola response improvement plan progress report. U.S. Department of Health and Human Services. https:\/\/www.phe.gov\/Preparedness\/responders\/ebola\/Documents\/erip-report-2017.pdf . Accessed 3 May 2017, Washington, DC"},{"key":"53_CR57","unstructured":"U.S. National Institutes of Health (2017a) A study to evaluate the safety and immunogenicity of a candidate Ebola vaccine in adults. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02485301?term=nct02485301&rank=1 . Accessed 24 Mar 2017"},{"key":"53_CR58","unstructured":"U.S. National Institutes of Health (2017b) A study to evaluate the safety and immunogenicity of a candidate Ebola vaccine in children. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02548078?term=nct02548078&rank=1 . Accessed 24 Mar 2017"},{"issue":"1","key":"53_CR59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/21645515.2016.1225637","volume":"13","author":"Y Wang","year":"2017","unstructured":"Wang Y, Li J, Hu Y, Liang Q, Wei M, Zhu F (2017) Ebola vaccines in clinical trial: the promising candidates. Hum Vaccin Immunother 13(1):153\u2013168. doi: 10.1080\/21645515.2016.1225637","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl 2","key":"53_CR60","doi-asserted-by":"publisher","first-page":"S430","DOI":"10.1086\/520583","volume":"196","author":"KL Warfield","year":"2007","unstructured":"Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196(Suppl 2):S430\u2013S437. doi: 10.1086\/520583","journal-title":"J Infect Dis"},{"key":"53_CR61","unstructured":"Webmaster Administration (2017) PREVAIL SMC ends March 2017 on high note. Daily Observer, Monrovia, LR, 6 Apr 2017. https:\/\/www.liberianobserver.com\/news\/prevail-smc-ends-March-2017-on-high-note\/ . Access 13 Apr 2017"},{"key":"53_CR62","doi-asserted-by":"publisher","unstructured":"Widdowson MA, Schrag SJ, Carter RJ, Carr W, Legardy-Williams J, Gibson L, Lisk DR, Jalloh MI, Bash-Taqi DA, Kargbo SA, Idriss A, Deen GF, Russell JB, McDonald W, Albert AP, Basket M, Callis A, Carter VM, Ogunsanya KR, Gee J, Pinner R, Mahon BE, Goldstein ST, Seward JF, Samai M, Schuchat A (2016) Implementing an Ebola vaccine study\u2014Sierra Leone. MMWR Suppl 65(3):98\u2013106. doi: 10.15585\/mmwr.su6503a14 https:\/\/www.cdc.gov\/mmwr\/volumes\/65\/su\/su6503a14.htm?s_cid=su6503a14_w . Accessed 29 June 2017","DOI":"10.15585\/mmwr.su6503a14"},{"key":"53_CR63","unstructured":"World Health Organization (2014a) Ebola virus disease in Guinea. World Health Organization. http:\/\/www.afro.who.int\/en\/disease-outbreaks\/outbreak-news\/4063-ebola-virus-disease-in-guinea.html . Accessed 13 Apr 2017"},{"key":"53_CR64","unstructured":"World Health Organization (2014b) Liberia: working with communities is the key to stopping Ebola. World Health Organization. http:\/\/www.who.int\/features\/2014\/liberia-stopping-ebola\/en\/ . Accessed 27 Mar 2017"},{"key":"53_CR65","unstructured":"World Health Organization (2014c) Meeting summary of the WHO consultation on potential Ebola therapies and vaccines. World Health Organization. http:\/\/apps.who.int\/iris\/bitstream\/10665\/136103\/1\/WHO_EVD_Meet_EMP_14.1_eng.pdf?ua=1 . Accessed 27 Apr 2017"},{"key":"53_CR66","unstructured":"World Health Organization (2014d) Statement on the 1st meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in West Africa. World Health Organization. http:\/\/www.who.int\/mediacentre\/news\/statements\/2014\/ebola-20140808\/en\/ . Accessed 28 Mar 2017"},{"key":"53_CR67","unstructured":"World Health Organization (2014e) WHO high-level meeting on Ebola vaccines access and financing: summary report. World Health Organization. http:\/\/apps.who.int\/iris\/bitstream\/10665\/137184\/1\/WHO_EVD_Meet_EMP_14.2_eng.pdf?ua=1 . Accessed 12 May 2017"},{"key":"53_CR68","unstructured":"World Health Organization (2015a) Factors that contributed to undetected spread of the Ebola virus and impeded rapid containment. One year into the Ebola epidemic. World Health Organization. http:\/\/www.who.int\/csr\/disease\/ebola\/one-year-report\/factors\/en\/ . Accessed 27 Mar 2017"},{"key":"53_CR69","unstructured":"World Health Organization (2015b) One year into the Ebola epidemic: a deadly tenacious and unforgiving virus. World Health Organization. http:\/\/www.who.int\/csr\/disease\/ebola\/one-year-report\/introduction\/en\/ Accessed 14 Apr 2017"},{"key":"53_CR70","unstructured":"World Health Organization (2016a) Ebola virus disease: situation report. World Health Organization. http:\/\/apps.who.int\/iris\/bitstream\/10665\/208883\/1\/ebolasitrep_10Jun2016_eng.pdf?ua=1 . Accessed 28 Mar 2017"},{"key":"53_CR71","unstructured":"World Health Organization (2016b) Graph of new confirmed cases per epi per week for Guinea. World Health Organization. http:\/\/apps.who.int\/gho\/data\/view.ebola-sitrep.ebola-country-GIN-20160511-graph?lang=en . Accessed 11 July 2017"},{"key":"53_CR72","unstructured":"World Health Organization (2016c) Graph of new confirmed cases per epi per week for Sierra Leone. World Health Organization. http:\/\/apps.who.int\/gho\/data\/view.ebola-sitrep.ebola-country-SLE-20160511-graph . Accessed 11 July 2017"},{"key":"53_CR73","unstructured":"World Health Organization (2016d) Graph of new confirmed caseswe per epi week for Liberia. World Health Organization. http:\/\/apps.who.int\/gho\/data\/view.ebola-sitrep.ebola-country-LBR-20160511-graph . Accessed 11 July 2017"},{"key":"53_CR02","unstructured":"World Health Organization (2016e) Progress report on the development of the WHO health emergencies programme, 30 March 2016, WHO, Geneva. http:\/\/www.who.int\/about\/who_reform\/emergencycapacities\/emergency-programme\/en\/ . Accessed 30 August 2017"},{"issue":"10027","key":"53_CR74","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/s0140-6736(16)30127-1","volume":"387","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Feng S, Cowling BJ (2016) Changes in the primary outcome in Ebola vaccine trial. Lancet 387(10027):1509. doi: 10.1016\/s0140-6736(16)30127-1","journal-title":"Lancet"},{"issue":"9984","key":"53_CR75","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/s0140-6736(15)60553-0","volume":"385","author":"FC Zhu","year":"2015","unstructured":"Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, Zhang JL, Wang WJ, Duan L, Chu K, Liang Q, Hu JL, Luo L, Zhu T, Wang JZ, Chen W (2015) Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385(9984):2272\u20132279. doi: 10.1016\/s0140-6736(15)60553-0","journal-title":"Lancet"}],"container-title":["Current Topics in Microbiology and Immunology","Marburg- and Ebolaviruses"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2017_53","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T11:18:31Z","timestamp":1570101511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/82_2017_53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319689463","9783319689487"],"references-count":77,"URL":"https:\/\/doi.org\/10.1007\/82_2017_53","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}